Ohio Peptide Research Regulatory Overview
Federal and state regulatory context for research-grade peptide compounds in Ohio. Informational summary for scientific researchers and research institutions.
Disclaimer: This page provides general regulatory context for informational purposes only and does not constitute legal advice. Researchers should consult applicable federal and state regulations and qualified legal counsel before making any decisions based on this content.
Federal Regulatory Context
At the federal level, research-grade peptide compounds available from research chemical suppliers are not currently scheduled under the CSA and are therefore not subject to DEA registration requirements applicable to controlled substances. FDA oversight requires that these compounds be sold under the Research Use Only designation for legitimate scientific research purposes. Procurement of research-grade peptides for in vitro laboratory research operates under general federal commerce regulations rather than DEA controlled substance compliance frameworks.
Ohio State Context
Ohio Revised Code Chapter 3719 establishes state controlled substance schedules that track federal CSA scheduling. Ohio does not currently impose scheduling restrictions on unscheduled research-grade peptide compounds beyond federal requirements. Ohio also does not maintain a state analog act applicable to the research peptide compound classes in the standard research chemical catalog. Researchers at Ohio institutions should consult institutional compliance offices for guidance on procurement and use of research chemicals in their specific institutional context.
Research Overview
Ohio has a substantial biomedical research infrastructure through the Cleveland Clinic, Ohio State University Wexner Medical Center, Case Western Reserve University School of Medicine, University of Cincinnati College of Medicine, and Nationwide Children's Hospital Research Institute. Research-grade peptide compounds for in vitro laboratory research are regulated at the federal level under FDA and DEA jurisdiction. Ohio Revised Code Chapter 3719 (the Ohio Controlled Substances Act) establishes state scheduling that tracks federal CSA scheduling and does not currently include the unscheduled research-grade peptide compounds such as BPC-157, TB-500, GHK-Cu, NAD+, and Epithalon. Ohio research institutions operate active compliance programs for research chemical procurement.
- •Cleveland Clinic Lerner Research Institute
- •Ohio State University Wexner Medical Center
Commonly Researched Compounds
Research-grade compounds commonly procured by institutions in Ohio for in vitro and preclinical research programs.
Frequently Asked Questions
Legal Disclaimer
The information on this page is provided for general informational and educational purposes only. It does not constitute legal advice and should not be relied upon as such. Laws and regulations governing research chemicals, peptides, and related compounds vary by jurisdiction and are subject to change. Researchers and organizations should consult a qualified legal professional familiar with federal and state law applicable to their specific situation before making any decisions based on this content. Spartan Peptides does not provide legal counsel and makes no representations regarding the legal status of any compound in any specific jurisdiction.
Explore All Research-Grade Compounds
Browse the full Spartan Peptides research compound catalog. All compounds are research-grade, supplied as lyophilized powder with certificate of analysis, for in vitro laboratory research use only.